Novo’s US boss wants to kick Tresiba sales into gear

Novo Nordisk has not captured as much of the lucrative diabetes market in the US as it had hoped. Blockbuster hopeful Tresiba holds the key to success, but it’s easier said than done.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Reuters: Kinesere vil købe J&J's diabetesforretning

Amerikanske Johnson & Johnson kan være på vej til at sælge sin forretning for diabetesudstyr for godt 24 mia. kr., efter flere kinesiske aktører ifølge Reuters har vist interesse i at overtage forretningsdelen.

Related articles